AMGN: Transformative oncology pipeline advances with T cell engagers, AI, and precision therapies

Amgen (AMGN) is making significant strides in its oncology research and development, focusing on transformative therapies for both solid and hematological cancers. Key advancements include T cell engagers, small molecules, and selective ADCs. The company’s existing cancer treatments like IMDELLTRA, LUMAKRAS, and BLINCYTO are being expanded, while AI and biomarker strategies are integrated to drive further innovation and pipeline growth.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)